Literature DB >> 12650610

Transcriptional regulation of osteopontin and the metastatic phenotype: evidence for a Ras-activated enhancer in the human OPN promoter.

David T Denhardt1, Devra Mistretta, Ann F Chambers, Shuba Krishna, Joseph F Porter, Srilatha Raghuram, Susan R Rittling.   

Abstract

Elevated osteopontin (OPN) transcription often correlates with increased metastatic potential of transformed cells, and in several model systems OPN--whether produced by the tumor cells or by stromal cells - has been shown to enhance metastatic ability. Sequence elements in the OPN promoter have been identified on the basis of their ability to interact with protein factors associated with the tumorigenic process in one or more cell lineages. One of these is a Ras-activated enhancer (RAE) that binds a protein, the Ras-response factor (RRF), whose ability to form a complex with the RAE is stimulated by Ras signaling in fibroblasts and epithelial cells. Another is the T cell factor-4 binding site, which in the OPN promoter can retard OPN transcription when bound by the Tcf-4 protein. In Rama 37 rat mammary epithelial cells Tcf-4 suppresses OPN transcription and the metastatic phenotype. A third promoter segment consists of two sequences in the -94 to -24 region of the human OPN promoter able to bind several known transcription factors, including Sp1, Myc and Oct-1, which may act synergistically to stimulate OPN transcription in malignant astrocytic cells. Although expression of other genes may also be regulated by these transcription factors, evidence suggests that often OPN alone can stimulate metastasis. In this communication we address two issues: (1) How does OPN facilitate the metastatic phenotype? (2) What mechanisms are responsible for the increase in OPN transcription in metastatic cells?

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12650610     DOI: 10.1023/a:1022550721404

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  90 in total

Review 1.  Osteopontin: a versatile regulator of inflammation and biomineralization.

Authors:  C M Giachelli; S Steitz
Journal:  Matrix Biol       Date:  2000-12       Impact factor: 11.583

2.  Characterization of the rat osteopontin gene. Evidence for two vitamin D response elements.

Authors:  A L Ridall; E L Daane; D P Dickinson; W T Butler
Journal:  Ann N Y Acad Sci       Date:  1995-04-21       Impact factor: 5.691

3.  The identification of osteopontin as a metastasis-related gene product in a rodent mammary tumour model.

Authors:  A J Oates; R Barraclough; P S Rudland
Journal:  Oncogene       Date:  1996-07-04       Impact factor: 9.867

4.  Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling.

Authors:  Deepak Agrawal; Tingan Chen; Rosalyn Irby; John Quackenbush; Ann F Chambers; Marianna Szabo; Alan Cantor; Domenico Coppola; Timothy J Yeatman
Journal:  J Natl Cancer Inst       Date:  2002-04-03       Impact factor: 13.506

5.  Transcriptional regulation of the human osteopontin promoter: functional analysis and DNA-protein interactions.

Authors:  D Wang; S Yamamoto; N Hijiya; E N Benveniste; C L Gladson
Journal:  Oncogene       Date:  2000-11-23       Impact factor: 9.867

6.  Soluble osteopontin inhibits apoptosis of adherent endothelial cells deprived of growth factors.

Authors:  S A Khan; C A Lopez-Chua; J Zhang; L W Fisher; E S Sørensen; D T Denhardt
Journal:  J Cell Biochem       Date:  2002       Impact factor: 4.429

Review 7.  The functional and clinical roles of osteopontin in cancer and metastasis.

Authors:  K A Furger; R K Menon; A B Tuck; V H Bramwell; A F Chambers
Journal:  Curr Mol Med       Date:  2001-11       Impact factor: 2.222

8.  Osteopontin expression and distribution in human carcinomas.

Authors:  L F Brown; A Papadopoulos-Sergiou; B Berse; E J Manseau; K Tognazzi; C A Perruzzi; H F Dvorak; D R Senger
Journal:  Am J Pathol       Date:  1994-09       Impact factor: 4.307

9.  Osteopontin expression in a group of lymph node negative breast cancer patients.

Authors:  A B Tuck; F P O'Malley; H Singhal; J F Harris; K S Tonkin; N Kerkvliet; Z Saad; G S Doig; A F Chambers
Journal:  Int J Cancer       Date:  1998-10-23       Impact factor: 7.396

10.  A secreted phosphoprotein marker for neoplastic transformation of both epithelial and fibroblastic cells.

Authors:  D R Senger; B B Asch; B D Smith; C A Perruzzi; H F Dvorak
Journal:  Nature       Date:  1983-04-21       Impact factor: 49.962

View more
  34 in total

1.  Osteopontin, an oxidant stress sensitive cytokine, up-regulates collagen-I via integrin α(V)β(3) engagement and PI3K/pAkt/NFκB signaling.

Authors:  Raquel Urtasun; Aritz Lopategi; Joseph George; Tung-Ming Leung; Yongke Lu; Xiaodong Wang; Xiaodong Ge; Maria Isabel Fiel; Natalia Nieto
Journal:  Hepatology       Date:  2012-02       Impact factor: 17.425

Review 2.  Role of osteopontin in the pathophysiology of cancer.

Authors:  Lalita A Shevde; Rajeev S Samant
Journal:  Matrix Biol       Date:  2014-03-19       Impact factor: 11.583

3.  Apc(MIN) modulation of vitamin D secosteroid growth control.

Authors:  Haibo Xu; Gary H Posner; Michael Stevenson; Frederick C Campbell
Journal:  Carcinogenesis       Date:  2010-05-20       Impact factor: 4.944

4.  Elevated phosphate activates N-ras and promotes cell transformation and skin tumorigenesis.

Authors:  Corinne E Camalier; Matthew R Young; Gerd Bobe; Christine M Perella; Nancy H Colburn; George R Beck
Journal:  Cancer Prev Res (Phila)       Date:  2010-02-09

5.  Osteopontin expression in intratumoral astrocytes marks tumor progression in gliomas induced by prenatal exposure to N-ethyl-N-nitrosourea.

Authors:  Taichang Jang; Todd Savarese; Hoi Pang Low; Sunchin Kim; Hannes Vogel; David Lapointe; Timothy Duong; N Scott Litofsky; James M Weimann; Alonzo H Ross; Lawrence Recht
Journal:  Am J Pathol       Date:  2006-05       Impact factor: 4.307

6.  Osteopontin regulates human glioma cell invasiveness and tumor growth in mice.

Authors:  Hsun-Jin Jan; Chin-Cheng Lee; Yung-Luen Shih; Dueng-Yuan Hueng; Hsin-I Ma; Jing-Huei Lai; Hen-Wei Wei; Horng-Mo Lee
Journal:  Neuro Oncol       Date:  2009-12-23       Impact factor: 12.300

7.  Potential relationship between hepatobiliary osteopontin and peroxisome proliferator-activated receptor alpha expression following ethanol-associated hepatic injury in vivo and in vitro.

Authors:  Jin-Hyung Lee; Atrayee Banerjee; Yoshi Ueno; Shashi K Ramaiah
Journal:  Toxicol Sci       Date:  2008-08-14       Impact factor: 4.849

8.  Expression of phosphorylated-STAT3 and osteopontin and their correlation in melanoma.

Authors:  Yan Wu; Ping Jiang; Yun Lin; Siyuan Chen; Nengxing Lin; Jiawen Li
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2009-04-28

Review 9.  Role of hyaluronan in glioma invasion.

Authors:  Jong Bae Park; Hee-Jin Kwak; Seung-Hoon Lee
Journal:  Cell Adh Migr       Date:  2008-07-21       Impact factor: 3.405

Review 10.  Astrocyte elevated gene-1: recent insights into a novel gene involved in tumor progression, metastasis and neurodegeneration.

Authors:  Luni Emdad; Devanand Sarkar; Zao-Zhong Su; Seok-Geun Lee; Dong-Chul Kang; Jeffrey N Bruce; David J Volsky; Paul B Fisher
Journal:  Pharmacol Ther       Date:  2007-02-24       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.